Sökning: onr:"swepub:oai:DiVA.org:uu-513000" >
Immuno-oncological ...
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs : an in vitro assessment
-
- Selvin, Tove (författare)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
-
- Berglund, Malin (författare)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
-
- Lenhammar, Lena (författare)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
-
visa fler...
-
- Lindskog, Magnus (författare)
- Uppsala universitet,Cancerprecisionsmedicin,Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
-
- Jarvius, Malin (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för farmaceutisk biovetenskap
-
- Larsson, Rolf (författare)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
-
- Nygren, Peter (författare)
- Uppsala universitet,Cancerprecisionsmedicin
-
- Fryknäs, Mårten (författare)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
-
- Andersson, Claes R. (författare)
- Uppsala universitet,Cancerfarmakologi och beräkningsmedicin
-
visa färre...
-
(creator_code:org_t)
- BioMed Central (BMC), 2024
- 2024
- Engelska.
-
Ingår i: BMC Pharmacology & Toxicology. - : BioMed Central (BMC). - 2050-6511. ; 25:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundIt has become evident in the field of oncology that the outcome of medical treatment is influenced by the combined effect exerted on both cancer- and immune cells. Therefore, we evaluated potential immunological effects of 46 standard anticancer agents and 22 commonly administered concomitant non-cancer drugs.MethodsWe utilized a miniaturized in vitro model system comprised of fluorescently labeled human colon and lung cancer cell lines grown as monocultures and co-cultured with activated peripheral blood mononuclear cells (PBMCs). The Bliss Independence Model was then applied to detect antagonism and synergy between the drugs and activated immune cells.ResultsAmong the standard anticancer agents, tyrosine kinase inhibitors (TKIs) stood out as the top inducers of both antagonism and synergy. Ruxolitinib and dasatinib emerged as the most notably antagonistic substances, exhibiting the lowest Bliss scores, whereas sorafenib was shown to synergize with activated PBMCs. Most concomitant drugs did not induce neither antagonism nor synergy. However, the statins mevastatin and simvastatin were uniquely shown to synergize with activated PBMC at all tested drug concentrations in the colon cancer model.ConclusionWe utilized a miniaturized tumor-immune model to enable time and cost-effective evaluation of a broad panel of drugs in an immuno-oncology setting in vitro. Using this approach, immunomodulatory effects exerted by TKIs and statins were identified.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Anticancer drugs
- concomitant drugs
- immuno-oncology
- in vitro modeling
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas